Labcorpvs.Natera
LH vs NTRA · both in Diagnostics, part of the Medicine, pharma & life science value chain: Tests, imaging and assays that support clinical decision-making.
Natera is about 2.2× larger than Labcorp by market cap; year to date, Natera leads (+72.7% vs +24.4%).
Side by side
| LH | NTRA | |
|---|---|---|
| Market cap | $25.5B | $55.6B |
| Price | $314.20 | $390.79 |
| Today | +0.7% | −1.2% |
| Return YTD | +24.4% | +72.7% |
| Return 1Y | +11.6% | +134.7% |
| Since June 26, 2026 | +15.7% | +49.2% |
| P/E | 25.4 | — |
| P/S | 1.8 | 20.5 |
| P/B | 3.0 | 30.5 |
Data as of 2026-10-08 · updates daily after U.S. close
Since June 26, 2026: the change in the closing price, from the daily closes Sectivia records itself since that date.
The two companies
LabcorpLH
Samples from across the US end up in Labcorp's laboratories, which handle routine clinical testing alongside genomics and specialty assays. A contract research arm works for drug developers.
Full LH profile →NateraNTRA
Genetic testing put to three uses: Panorama screens pregnancies, Signatera works in oncology, and a third line covers transplant medicine.
Full NTRA profile →More LH & NTRA comparisons
Other head-to-heads in the Diagnostics segment.